A single-dose, open-label study of TX000045 in patients with CpcPH or IpcPH and HFpEF.

2023-508969-32-00 Protocol TX000045-002 Human pharmacology (Phase I) - Other Ended

Start 8 Jul 2024 · End 3 Sep 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol TX000045-002

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 35
Countries 1
Sites 1

Combined postcapillary and precapillary pulmonary hypertension / Isolated postcapillary pulmonary hypertension

Key facts

Sponsor
Tectonic Therapeutic Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
8 Jul 2024 → 3 Sep 2025
Decision date (initial)
2024-04-04
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Combined postcapillary and precapillary pulmonary hypertension / Isolated postcapillary pulmonary hypertension

VersionLevelCodeTermSystem organ class
21.1 PT 10037400 Pulmonary hypertension 100000004855

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Tectonic Therapeutic Inc.

Sponsor organisation
Tectonic Therapeutic Inc.
Address
490 Arsenal Way
City
Watertown
Postcode
02472-2988
Country
United States

Scientific contact point

Organisation
Tectonic Therapeutic Inc.
Contact name
Anthony Muslin

Public contact point

Organisation
Tectonic Therapeutic Inc.
Contact name
Anthony Muslin

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 10 1
Rest of world
Moldova, Republic of, Georgia
25

Investigational sites

Netherlands

1 site · Ended
Universitair Medisch Centrum Groningen
Cardiology, Hanzeplein 1, 9713 GZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-07-08 2025-09-02 2024-08-21 2025-01-15

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-21 Netherlands Acceptable
2024-04-04
2024-04-04
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-27 Netherlands Acceptable
2024-10-14
2024-10-14
3 SUBSTANTIAL MODIFICATION SM-2 2025-04-28 Netherlands Acceptable
2025-05-13
2025-05-13
4 SUBSTANTIAL MODIFICATION SM-3 2025-07-31 Netherlands Acceptable
2025-09-01
2025-09-02